title: Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis?
authors.forename: P
authors.initials: P
authors.lastname: Pagliano
authors.forename: V
authors.initials: V
authors.lastname: Attanasio
authors.forename: U
authors.initials: U
authors.lastname: Fusco
authors.forename: D A
authors.initials: DA
authors.lastname: Mohamed
authors.forename: M
authors.initials: M
authors.lastname: Rossi
authors.forename: F S
authors.initials: FS
authors.lastname: Faella
mesh_terms: D032161:Antirrhinum / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008088:Listeriosis / Q000139:chemically induced*; D016920:Meningitis, Bacterial / Q000139:chemically induced*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D012307:Risk Factors
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept